Discover the latest industry insights at the 2026 Annual Meeting through engaging educational and product-focused sessions. These presentations give exhibiting companies a platform to unveil ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE:LLY) received a positive regulatory ...

A concerning program by Eli Lilly ties increased copay assistance for one of its top-selling brand-name drugs, tirzepatide (Zepbound), to having a prescription for another, ixekizumab (Taltz). Called ...

Ixekizumab and tirzepatide administered concomitantly was superior to ixekizumab alone in achieving complete skin clearance and at least a 10% weight reduction. The concomitant use of ixekizumab and ...

Eli Lilly and Co. (NYSE: LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound ...

We explore the FDA’s expansion of Wakix as the first non-scheduled treatment for pediatric cataplexy; a Taltz and Zepbound combo shows promise in skin clearance for patients with psoriasis and obesity ...

Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with plaque psoriasis and obesity or ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which ...

Eli Lilly (LLY) announced on Wednesday that a late-stage trial designed to test a combination regimen containing its weight loss therapy Zepbound and psoriasis therapy Taltz reached the main goals.

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. Chalk up another new potential expansion for Lilly as it has ...

At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight loss In ...